Pharmaceutical company touts 'breakthrough' cancer treatment


Patients participating in a trial for a new lung cancer treatment have shown signs of improved health, leading the pharmaceutical company behind the study to hail a major "breakthrough” in the field.

>> Read more trending news

The American company Bristol-Myers Squibb reported Monday that lung cancer patients treated with a combination of its anti-tumor drug Opdivo and its melanoma drug Yervoy showed encouraging results.

According to the company, the treatment fared better than chemotherapy for individuals with "first-line advanced non-small cell lung cancer," known as NSCLC.

>> Related: Just one drink a day can increase your risk of cancer, study warns

"This Phase 3 study shows superior PFS (progression-free survival) with first-line combination immunotherapy in a predefined population of NSCLC patients with high TMB (tumor mutation burden)," Dr. Matthew D. Hellmann, study investigator and medical oncologist at Memorial Sloan Kettering Cancer Center, said in a press release.

Dr. Giovanni Caforio, chairman and chief executive officer of Bristol-Myers Squibb, said that his company sees the results as "a breakthrough in cancer research and a meaningful step forward in determining which first-line lung cancer patients may benefit most from the combination of Opdivo and Yervoy."

>> On AJC.com: 7 surprising things that can increase your risk of cancer

"These findings attest to our deep understanding of cancer biology, leading translational medicine capabilities and commitment to developing new approaches for cancer patients," he added.

The treatment trials are currently in their final phase, meaning the next step is to seek approval from the Food and Drug Administration to market the drug combination as a treatment for this specific condition. A panel of experts formed to assess the data recommended that the clinical trial move forward, despite some modifications made during the trial, according to the company.

>> Related: New cancer 'vaccine' completely wipes out tumors in mice -- human trials are on way

Bristol-Myers Squibb has been a pioneer in immunotherapy, according to Reuters. But some analysts are still holding out to see whether or not the treatment will be a success.

"Overall survival is what matters," BMO Capital Markets analyst Alex Arfaei said, explaining that regulators prefer that standard.

"The survival benefit may not be that great," he added, pointing to other new promising treatments.

One analyst called the study "a clear win" for the company, but another cautioned that the report is "positive but unquantified data," according to Bloomberg.

Critics questioned whether the pharmaceutical company’s clinical trial design change may have sullied the results.

>> Related: Long-term aspirin users at lower risk of cancer, study concludes

According to MarketWatch, researchers made changes to the Phase 3 trial, called CheckMate-227, while it was already ongoing.

Bristol-Myers management addressed the concerns Monday in a conference call, stating that it responded to emerging science and only made changes after conversations with the Food and Drug Administration.

Nonetheless, the company is hailing the trials as "a true example" of "innovation."

>> On AJC.com: ‘One-stop’ blood test to detect cancer shows promise, scientists say

Overall survival data from the Opdivo and Yervoy combination trial will be released near the end of 2018 or early in 2019 the company said.

Already, Opdivo is the company's best-selling drug, reporting sales of $4.95 billion globally last year.

"By harnessing the body's own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers," Bristol-Myers Squibb explained.

>> Related: 72 major genetic risk factors for breast cancer identified in new study

The new trials will likely increase the drug's profitability as they further demonstrate its benefits, the company said. However, Seamus Fernandez, an analyst at Leerink Partners, pointed out that it remains to be seen whether combining Opdivo with Yervoy provides better results than taking the drug alone.

For now, Bristol-Myers Squibb is thanking the patients who participated in the trial leading to the "breakthrough."

"We would like to thank the patients and researchers who participated in these clinical trials — without whom this scientific advance would not be realized," the company said in a statement.


Reader Comments ...


Next Up in Nation & World

Chrissy Teigen reveals second baby’s due date
Chrissy Teigen reveals second baby’s due date

Soon-to-be mom of two Chrissy Teigen stopped by “The Ellen DeGeneres Show” to dish about her pregnancy Monday. The model and cookbook author revealed that she and singer John Legend’s second bundle of joy is due in June. >> Read more trending news  “I’m having a baby boy in the spring,” she told DeGeneres...
Florida gun owner surrenders assault rifle after Parkland high school massacre
Florida gun owner surrenders assault rifle after Parkland high school massacre

A Florida man spurred by the massacre that killed 17 people at a Parkland high school last week has “put (his) money where (his) mouth is” and surrendered his assault rifle to authorities. Ben Dickmann, 40, wrote on Friday, in a Facebook post that has since gone viral, that he decided to lead by example. “I own this rifle,&rdquo...
Trump fumes about Russia investigation as nation mourns
Trump fumes about Russia investigation as nation mourns

As the nation mourned, President Donald Trump kept largely silent about the Florida school shooting victims and the escalating gun control debate, instead raging at the FBI for what he perceived to be a fixation on the Russia investigation at the cost of failing to deter the attack. From the privacy of Mar-a-Lago, Trump vented about the investigation...
Girl, 16, killed when UTV crashes into Georgia lake
Girl, 16, killed when UTV crashes into Georgia lake

A 16-year-old girl was killed when the utility terrain vehicle in which she was riding crashed and went into a lake, authorities said. Kate Jones, 16, of Athens, was submerged when the UTV rolled into the lake on private property, Oconee County Sheriff Scott Berry said on Facebook. The incident happened about midnight. A deputy and a firefighter dived...
Meet Janice Bryant Howroyd, the first African-American woman to run a $1 billion business
Meet Janice Bryant Howroyd, the first African-American woman to run a $1 billion business

Janice Bryant Howroyd, 65, is founder and chief executive of Act 1 Group, an employment agency that also provides consulting and business services, including background checks and screening. She’s the first African-American woman to operate a company that generates more than $1 billion in annual revenue, according to Black Enterprise Magazine...
More Stories